TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Granules India Limited ( (IN:GRANULES) ) is now available.
Granules India Limited announced that its subsidiary, Granules Pharmaceuticals, Inc., received an Establishment Inspection Report from the US FDA following a Pre-Approval Inspection for a first-to-file controlled substance ANDA. The inspection, conducted in June 2025, resulted in one observation that has since been resolved, indicating the company’s commitment to maintaining regulatory standards.
More about Granules India Limited
Granules India Limited operates in the pharmaceutical industry, focusing on the production of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages. The company is known for its emphasis on quality and regulatory compliance, serving a global market.
Average Trading Volume: 77,944
Technical Sentiment Signal: Strong Buy
Current Market Cap: 139.1B INR
See more insights into GRANULES stock on TipRanks’ Stock Analysis page.